This company has a problem:
They're shorting this down, and closing the short when the price drops.
Shares Short (Oct 14, 2022) 4 ----- 37.76k
Short Ratio (Oct 14, 2022) 4 ----- 1.77
Short % of Float (Oct 14, 2022) 4 ----- 0.43%
Short % of Shares Outstanding (Oct 14, 2022) 4 ----- 0.29%
Shares Short (prior month Sep 15, 2022) 4 ----- 5.84k
At August 20, 2021, the registrant had 12,904,574 shares of Common Stock
At August 5, 2022, the registrant had 12,977,234 shares of Common Stock
They're shorting this down, and closing the short when the price drops.
Shares Short (Oct 14, 2022) 4 ----- 37.76k
Short Ratio (Oct 14, 2022) 4 ----- 1.77
Short % of Float (Oct 14, 2022) 4 ----- 0.43%
Short % of Shares Outstanding (Oct 14, 2022) 4 ----- 0.29%
Shares Short (prior month Sep 15, 2022) 4 ----- 5.84k
At August 20, 2021, the registrant had 12,904,574 shares of Common Stock
At August 5, 2022, the registrant had 12,977,234 shares of Common Stock
It is, what it is.
Recent RNAZ News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/26/2026 10:46:35 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/26/2026 10:43:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:15:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2026 04:15:17 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/08/2026 09:20:58 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/30/2026 09:24:06 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:15:15 PM
- TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University • PR Newswire (US) • 04/27/2026 12:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:17:42 PM
- TransCode Therapeutics signs financing deal worth up to $20 million • IH Market News • 04/07/2026 01:51:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 12:37:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:16 PM
- TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 • PR Newswire (US) • 04/07/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/03/2026 09:06:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:05:39 PM
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Pa • PR Newswire (US) • 03/03/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:10:39 PM
- TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development • PR Newswire (US) • 02/23/2026 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:10:42 PM
- TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 • PR Newswire (US) • 02/05/2026 01:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
- TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma • PR Newswire (US) • 01/06/2026 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/23/2025 09:17:28 PM
